SD-1008

SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway[1].

Product Specifications

CAS Number

[960201-81-4]

UNSPSC

12352005

Target

Apoptosis; JAK; STAT

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sd-1008.html

Purity

99.10

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1[C@H](C2=O)N([C@H](C=C2)[C@H]1C(OC)=O)CC3=CC=CC=C3)OC

Molecular Formula

C18H19NO5

Molecular Weight

329.35

References & Citations

[1]Duan Z, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007;72 (5) :1137-1145.